A panel of biomarkers including caspase-3 and d-dimer may differentiate acute stroke from stroke-mimicking conditions in the emergency department

Journal of Internal Medicine

Volumn 270, Issue 2, 2011, Pages 166-174

  Montaner, J ^a   Mendioroz, M ^a   Ribo M ^a   Delgado, P ^a   Quintana, M ^a   Penalba, A ^a   Chacon P ^a   Molina, C ^a   Fernandez Cadenas I ^a   Rosell, A ^a   Alvarez Sabin J ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Biomarkers; Caspase 3; Cerebral ischaemia; d dimer; Stroke

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM BINDING PROTEIN; CASPASE 3; CHIMERIN; D DIMER; GELATINASE B; NEUROTROPHIN 3; PROTEIN S100B; SECRETAGOGIN; UNCLASSIFIED DRUG;

ACUTE DISEASE; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; EMERGENCY WARD; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROUPS BY AGE AND SEX; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASPASE 3; CHIMERIN PROTEINS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NERVE GROWTH FACTORS; NEUROTROPHIN 3; PREDICTIVE VALUE OF TESTS; RECEPTORS, IMMUNOLOGIC; S100 PROTEINS; STROKE;

EID: 79960214808     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02329.x     Document Type: Article

References (31)

1. World Health Organization. World Health Report 2002. Geneva, Switzerland: WHO, 2002.
2. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke 1996; 27: 1459-66.
3. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-7.
4. Katzan IL, Hammer MD, Hixson ED et al. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004; 61: 346-50.
5. Ohwaki K, Yano E, Nagashima H, Hirata M, Nakagomi T, Tamura A. Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke 2004; 35: 1364-7.
6. Anderson CS. Medical management of acute intracerebral hemorrhage. Curr Opin Crit Care 2009; 15: 93-8.
7. Libman RB, Wirkowski E, Alvir J, Rao TH. Conditions that mimic stroke in the emergency department. Implications for acute stroke trials. Arch Neurol 1996; 53: 404.
8. Hand PJ, Kwan J, Lindley RI, Dennis MS, Wardlaw JM. Distinguishing between stroke and mimic at the bedside: the brain attack study. Stroke 2006; 37: 769-75.
9. Scott PA, Silbergleit R. Misdiagnosis of stroke in tissue plasminogen activator-treated patients: characteristics and outcomes. Ann Emerg Med 2003; 42: 611-8.
10. Montaner J, Perea-Gainza M, Delgado P et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 2008; 39: 2280-7.
11. Adams HP, Bendixen BH, Kappelle LJ et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 1993; 24: 35-41.
12. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinical subtypes of cerebral infarction. Lancet 1991; 337: 1521-6.
13. Brott T, Bogousslavsky J. Treatment of acute ischemic stroke. N Engl J Med 2000; 343: 710-22.
14. Zanette EM, Roberti C, Mancini G, Pozzilli C, Bragoni M, Toni D. Spontaneous middle cerebral artery reperfusion in acute ischemic stroke: a follow-up study with transcranial Doppler. Stroke 1995; 26: 430-3.
15. Grant EG, Benson CB, Moneta GL et al. Carotid artery stenosis: gray-scale and Doppler US diagnosis-Society of Radiologists in Ultrasound Consensus Conference. Radiology 2003; 229: 340-6.
16. Panteghini M. Role and importance of biochemical markers in clinical cardiology. Eur Heart J 2004; 25: 1187-96.
17. Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT. Novel diagnostic test for acute stroke. Stroke 2004; 35: 57-63.
18. Montaner J, Molina CA, Monasterio J et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107: 598-603.
19. Hou ST, MacManus JP. Molecular mechanisms of cerebral ischemia induced neuronal death. Int Rev Cytol 2002; 221: 93-148.
20. Love S, Barber R, Wilcock GK. Neuronal death in brain infarcts in man. Neuropathol Appl Neurobiol 2000; 26: 55-66.
21. Le DA, Wu Y, Huang Z et al. Caspase activation and neuroprotection in caspase-3-deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation. Proc Natl Acad Sci USA 2002; 99: 15188-93.
22. Kerr LE, McGregor AL, Amet LE et al. Mice overexpressing human caspase-3 appear phenotypically normal but exhibit increased apoptosis and larger lesion volumes in response to transient focal cerebral ischaemia. Cell Death Differ 2004; 11: 1102-11.
23. Rosell A, Cuadrado E, Alvarez-Sabín J et al. Caspase-3 is related to infarct growth alter human ischemic stroke. Neurosci Lett 2008; 430: 1-6.
24. Tohgi H, Kawashima M, Tamura K, Suzuki H. Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism. Stroke 1990; 21: 1663-7.
25. Ageno W, Finazzi S, Steidl L et al. Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes. Arch Intern Med 2002; 162: 2589-93.
26. Falcone C, Emanuele E, D'Angelo A et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005; 25: 1032-7.
27. Rosell A, Ortega-Aznar A, Alvarez-Sabín J et al. Increased brain expresión of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 2006; 37: 1399-406.
28. Gartner W, Lang W, Leutmetzer F, Domanovits H, Waldhäusl W, Wagner L. Cerebral expression and serum detectability of secretagogin, a recently cloned EF-hand Ca(2+)-binding protein. Cereb Cortex 2001; 11: 1161-9.
29. Laskowitz DT, Blessing R, Floyd J, White WD, Lynch JR. Panel of biomarkers predicts stroke. Ann NY Acad Sci 2005; 1053: 30.
30. Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC. Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke 2009; 40: 77-85.
31. Sairanen T, Szepesi R, Karjalainen-Lindsberg ML, Saksi J, Paetau A, Lindsberg PJ. Neuronal caspase-3 and PARP-1 correlate differentially with apoptosis and necrosis in ischemic human stroke. Acta Neuropathol 2009; 118: 541-52.